Abstract
e11516 Background: Polymorphisms in the aromatase CYP19A1 gene have been shown to alter aromatase activity as well as circulating steroid hormone levels in postmenopausal women. The aim was to verify the potential association between CYP19A1 genetic polymorphisms and clinical outcome of hormone therapy in hormone receptor (HR) - positive early breast cancer. Methods: Genotyping for CYP19A1 rs4646 (C/A) polymorphism was performed on 287 Chinese women with HR-positive early breast cancer in Zhejiang Cancer Hospital. Associations were evaluated between CYP19A1 rs4646 genotypes and disease-free survival (DFS). Results: Overall, women with the minor allele (AA or AC) had an improved DFS when compared with those carrying the homozygous common allele (CC) (62.7 months versus 55.6 months; HR, 0.745; 95% CI, 0.562-0.988; p = 0.04). The difference was further demonstrated by multivariate analyses (HR, 0.681; 95 % CI, 0.506-0.917; p = 0.011). In premenopausal women, AA genotype was associated with a prolonged DFS (9...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
